New hope for teens with severe skin disease: drug trial launches

NCT ID NCT06921850

Ongoing Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a drug called bimekizumab in teenagers (ages 9 to 17) with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The goal is to see how the drug moves through the body and if it is safe. About 40 participants will receive the drug and be monitored for side effects and drug levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Locations

Hs0006 40095

Wroclaw, Poland
Hs0006 40326

Berlin, Germany
Hs0006 40625

Lodz, Poland
Hs0006 40747

Mainz, Germany
Hs0006 40761

Warsaw, Poland
Hs0006 40845

Wroclaw, Poland
Hs0006 50175

Phoenix, Arizona, 85006, United States
Hs0006 50178

Clarkston, Michigan, 48346, United States
Hs0006 50199

Miami, Florida, 33136, United States
Hs0006 50201

Arlington, Texas, 76011, United States
Hs0006 50202

Fairborn, Ohio, 45324, United States
Hs0006 50684

Sacramento, California, 95815, United States
Hs0006 50706

Chapel Hill, North Carolina, 27516, United States
Hs0006 50707

Washington D.C., District of Columbia, 20010, United States
Hs0006 50708

Roseville, California, 95661, United States
Hs0006 50710

Fort Gratiot, Michigan, 48059, United States
Hs0006 50711

Troy, Michigan, 48084, United States
Hs0006 50712

Bowling Green, Kentucky, 42104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.